Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70:7-30.
 Wang X, Yao S, Xiao Z, Gong J, Liu Z, Han B, et al. Development and validation of a survival model for lung adenocarcinoma based on autophagy-associated genes. J Transl Med. 2020;18:149.
 Li J P, Hsieh M J, Chou Y E, Chao Y H, Tsao T C, Yang S F. CD44 Gene Polymorphisms as a Risk Factor for Susceptibility and Their Effect on the Clinicopathological Characteristics of Lung Adenocarcinoma in Male Patients. Int J Environ Res Public Health. 2020;17.
 Bray F, Ferlay J, Soerjomataram I, Siegel R L, Torre L A, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
 Miller K D, Nogueira L, Mariotto A B, Rowland J H, Yabroff K R, Alfano C M, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363-385.
 Chuang Y Y, Tran N L, Rusk N, Nakada M, Berens M E, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res. 2004;64:8271-5.
 Malecz N, McCabe P C, Spaargaren C, Qiu R, Chuang Y, Symons M. Synaptojanin 2, a novel Rac1 effector that regulates clathrin-mediated endocytosis. Curr Biol. 2000;10:1383-6.
 Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci Signal. 2015;8:ra7.
 Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, Kogo M. Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. Genes Cells. 2003;8:1019-27.
 Zhang Y, Li Z Y, Hou X X, Wang X, Luo Y H, Ying Y P, et al. Clinical significance and effect of AEG-1 on the proliferation, invasion, and migration of NSCLC: a study based on immunohistochemistry, TCGA, bioinformatics, in vitro and in vivo verification. Oncotarget. 2017;8:16531-16552.
 Yang X, Mo W, Fang Y, Wei G, Wei M, Dang Y, et al. Up-regulation of Polo-like Kinase 1 in nasopharyngeal carcinoma tissues: a comprehensive investigation based on RNA-sequencing, gene chips, and in-house tissue arrays. Am J Transl Res. 2018;10:3924-3940.
 Ioannidis J P, Patsopoulos N A, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335:914-6.
 Higgins J P, Thompson S G, Deeks J J, Altman D G. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
 Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786-801.
 Ando A, Hashimoto N, Sakamoto K, Omote N, Miyazaki S, Nakahara Y, et al. Repressive role of stabilized hypoxia inducible factor 1α expression on transforming growth factor β-induced extracellular matrix production in lung cancer cells. Cancer Sci. 2019;110:1959-1973.
 Cox T R, Erler J T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4:165-78.
 Lu P, Weaver V M, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196:395-406.
 Paolillo M, Schinelli S. Extracellular Matrix Alterations in Metastatic Processes. Int J Mol Sci. 2019;20.
 Buccione R, Orth J D, McNiven M A. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol. 2004;5:647-57.
 Chen W T. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool. 1989;251:167-85.
 Domagała-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp (Warsz). 2006;54:143-7.
 Barthelemy-Brichant N, David J L, Bosquée L, Bury T, Seidel L, Albert A, et al. Increased TGFbeta1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest. 2002;32:193-8.
 Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964-71.
 Bruna A, Darken R S, Rojo F, Ocaña A, Peñuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11:147-60.
 Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999;86:1455-62.
 Wikström P, Stattin P, Franck-Lissbrant I, Damber J E, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37:19-29.
 Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375-82.
 Oft M, Heider K H, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998;8:1243-52.
 Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66:2202-9.
 Bandyopadhyay A, Agyin J K, Wang L, Tang Y, Lei X, Story B M, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006;66:6714-21.
 Biswas S, Guix M, Rinehart C, Dugger T C, Chytil A, Moses H L, et al. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 2017;127:1116.
 Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93-115.
 Cai Z, Liu Q. Cell Cycle Regulation in Treatment of Breast Cancer. Adv Exp Med Biol. 2017;1026:251-270.
 Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138:255-71.
 Wang H, Ye L, Xing Z, Li H, Lv T, Liu H, et al. CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. Pathol Res Pract. 2019;215:152559.
 Ge H, Cheng N, Xu X, Yang Z, Hoffman R M, Zhu J. AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line. Anticancer Res. 2019;39:4637-4642.
 Cheng L, Yang Q, Li C, Dai L, Yang Y, Wang Q, et al. DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle. J Cell Mol Med. 2017;21:1532-1544.
 Luo J, Liu K, Yao Y, Sun Q, Zheng X, Zhu B, et al. DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell. Cancer Lett. 2019;453:45-56.
 Guo W, Sun S, Guo L, Song P, Xue X, Zhang H, et al. Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. J Cancer Res Clin Oncol. 2020;146:821-841.
 Wang F, Chen X, Yu X, Lin Q. Degradation of CCNB1 mediated by APC11 through UBA52 ubiquitination promotes cell cycle progression and proliferation of non-small cell lung cancer cells. Am J Transl Res. 2019;11:7166-7185.
 Ma Q. MiR-219-5p suppresses cell proliferation and cell cycle progression in esophageal squamous cell carcinoma by targeting CCNA2. Cell Mol Biol Lett. 2019;24:4.
 Gan Y, Li Y, Li T, Shu G, Yin G. CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res. 2018;10:5113-5124.
 Li F, Jin D, Guan L, Zhang C C, Wu T, Wang Y J, et al. CEP55 promoted the migration, invasion and neuroshpere formation of the glioma cell line U251. Neurosci Lett. 2019;705:80-86.
 Yin Y, Cai J, Meng F, Sui C, Jiang Y. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55. Cancer Biol Ther. 2018;19:306-315.
 Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 2014;35:4389-99.
 You B, Zhang K C. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55. Eur Rev Med Pharmacol Sci. 2018;22:7660-7670.
 Wu S, Wu D, Pan Y, Liu H, Shao Z, Wang M. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis. Pathol Res Pract. 2019;215:292-301.
 Zhao X, Zhou L L, Li X, Ni J, Chen P, Ma R, et al. Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis. Cancer Med. 2018;7:4678-4689.
 Sun Z Y, Wang W, Gao H, Chen Q F. Potential therapeutic targets of the nuclear division cycle 80 (NDC80) complexes genes in lung adenocarcinoma. J Cancer. 2020;11:2921-2934.
 Zhang M Y, Liu X X, Li H, Li R, Liu X, Qu Y Q. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis. Int J Med Sci. 2018;15:1676-1685.
 Zang X, Qian C, Ruan Y, Xie J, Luo T, Xu B, et al. Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients. Biomark Med. 2019;13:1349-1361.
 Bai Y, Xiong L, Zhu M, Yang Z, Zhao J, Tang H. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 2019;24:371-382.
 Li S, Xuan Y, Gao B, Sun X, Miao S, Lu T, et al. Identification of an eight-gene prognostic signature for lung adenocarcinoma. Cancer Manag Res. 2018;10:3383-3392.